This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System CI
Roth MKM Starts Accuray With Buy Rating, $9 Price Target MT
Quebec Cancer Center Is First in Canada to Treat Cancer Patients Using the Accuray Radixact System CI
Transcript : Accuray Incorporated, Q2 2024 Earnings Call, Jan 31, 2024
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q2 Revenue $107.2M, vs. Street Est of $106.7M MT
Accuray Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024 CI
Accuray Incorporated Announces the Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray Cyberknife System CI
Accuray Insider Sold Shares Worth $161,624, According to a Recent SEC Filing MT
B. Riley Trims Accuray's Price Target to $6.50 From $7.50 on Lower Multiple, Maintains Buy Rating MT
Transcript : Accuray Incorporated, Q1 2024 Earnings Call, Nov 07, 2023
Accuray Incorporated Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Earnings Flash (ARAY) ACCURAY INCORPORATED Reports Q1 Revenue $103.9M, vs. Street Est of $97.6M MT
Accuray Shares Rise After Securing Approval for Tomo C Radiation Therapy System in China MT
Accuray Secures Approval for Tomo C Radiation Therapy System in China MT
Transcript : Accuray Incorporated - Analyst/Investor Day
Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration CI
Accuray Partners With Limbus AI to Launch Online Adaptive Therapy for Radixact System MT
Accuray Incorporated and Limbus AI Unveil Online Adaptive Therapy Solution for Radixact System at American Society for Radiation Oncology Annual Meeting CI
Accuray Incorporated Opens the Doors of its New Global Training Facility, the Accuray Center for Education, Located At its Corporate Headquarters in Madison, Wisconsin CI
Accuray Gets US FDA Clearance for Addition of New Functionality to Radixact System for Breast Cancer Treatment MT
Accuray Incorporated Receives FDA Clearance for VitalHold on the Radixact System; Breast Cancer Treatment Option Will Also Be Available in the EU Market CI
Transcript : Accuray Incorporated, Q4 2023 Earnings Call, Aug 09, 2023
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q4 Revenue $118.3M, vs. Street Est of $121.7M MT
Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024 CI
Chart Accuray Incorporated
More charts
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.31 USD
Average target price
8.75 USD
Spread / Average Target
+278.79%
Consensus
  1. Stock Market
  2. Equities
  3. ARAY Stock
  4. News Accuray Incorporated
  5. Earnings Flash (ARAY) ACCURAY INCORPORATED Reports Q2 Revenue $116.3M, vs. Street Est of $102.9M